FMP

FMP

Enter

LUNG - Pulmonx Corporation

Financial Summary of Pulmonx Corporation(LUNG), Pulmonx Corporation, a medical technology company, provides minimally invasive devices for the treat

photo-url-https://financialmodelingprep.com/image-stock/LUNG.png

Pulmonx Corporation

LUNG

NASDAQ

Pulmonx Corporation, a medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. It offers Zephyr Endobronchial Valve, a solution for the treatment of bronchoscopic in adult patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also provides StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. It serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.

7.43 USD

0.01 (0.135%)

About

ceo

Mr. Steven S. Williamson

sector

Healthcare

industry

Medical - Devices

website

https://pulmonx.com

exchange

NASDAQ

Description

Pulmonx Corporation, a medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. It offers Zephyr Endobronchial Valve, a solution for the treatment of bronchoscopic in adult patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also provides StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help iden...

CIK

0001127537

ISIN

US7458481014

CUSIP

745848101

Address

700 Chesapeake Drive

Phone

650 364 0400

Country

US

Employee

279

IPO Date

Oct 1, 2020

Summary

CIK

0001127537

Exchange

NASDAQ

Industry

Medical - Devices

Sector

Healthcare

CUSIP

745848101

ISIN

US7458481014

Country

US

Price

7.43

Beta

0.6

Volume Avg.

567.97k

Market Cap

286.33M

Shares

-

52-Week

7.31-14.835

DCF

-0.07

ROE

-

ROA

-

Operating Margin

-

Debt/Equity

-

P/E

-4.64

P/B

-

Website

https://pulmonx.com

Historical Prices

We are unable to load the chart at this time.

fmp-logo

Financial Statement

We are unable to load the chart at this time.

fmp-logo

Earnings

We are unable to load the chart at this time.

fmp-logo

Upgrades and Downgrades

We are unable to load this data!

fmp-logo

People Also Watch

page loading card

Latest LUNG News

It looks like there's no news available.

fmp-logo
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep